Highlights for the Third Quarter of 2026
Revenue increased to
$23.1 million , compared to$12.3 million in Q3 2025Net Loss from Operations of
$2.7 million , compared to$0.9 million in Q3 2025Adjusted EBITDA loss of
$1.3 million , compared to$0.4 million in Q3 2025Launched the new TelyRx brand and website, making it easier for patients to find the treatments they need and which has led to a 17% improvement in revenue per visitor
Increased formulary to more than 500 everyday medications, expanding access to prescriptions across a broad range of healthcare needs
Announced expansion of operations in
Clearwater, Florida , which will more than triple capacity at theClearwater location
"Our third quarter reflects the discipline we bring to growing this business. We held revenue steady while narrowing our Adjusted EBITDA loss by more than half from the prior quarter," said
2026 Third Quarter Financial Results
Selected Financial Information
| (Thousands of except percentages) | For the three-month periods ended | |||||
| 2026 | 2025 | |||||
| Revenue | $ | 23,078 | $ | 12,337 | ||
| Gross Profit | 13,775 | 6,886 | ||||
| Gross Profit Margin | 60% | 56% | ||||
| Net Loss from Operations | (2,744 | ) | (947 | ) | ||
| Adjusted EBITDA1 | (1,277 | ) | (351 | ) | ||
| Cash & Cash Equivalents including Restricted Cash2 | 18,677 | 1,790 | ||||
(1) Non-IFRS measure. For further information, including a description of the composition of the measure and reconciliation of the measure to the comparable measures under IFRS, see the "Non-IFRS Financial Metrics" section of this press release.
(2) Includes
2026 Third Quarter Operational Results
Revenue was
Cost of revenue was
Gross profit was
Loss from operations was
Conference Call
The Company will host a conference call to discuss its third quarter of 2026 financial results on
About
TelyRx is an integrated digital healthcare platform that makes everyday prescription medications easier to access. Patients connect with independent, state-licensed healthcare providers who evaluate their needs and prescribe treatment when appropriate. Prescriptions are filled by TelyRx's licensed pharmacies and delivered directly to patients' doors. Serving patients across 49 U.S. states and all territories, TelyRx provides access to more than 500 common, FDA-approved medications for over 60 common health conditions through a seamless, convenient experience.
1) Non-IFRS Financial Metrics
In addition to the Company's financial results determined in accordance with IFRS, the Company presents non-IFRS measures such as Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("Adjusted EBITDA") and Free Cash Flow or FCF, as defined below that do not have standardized meanings prescribed by IFRS. We believe that Adjusted EBITDA, when taken together with the corresponding IFRS financial measures, provides meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. The Company considers Adjusted EBITDA and Free Cash Flow to be important measures because they help illustrate underlying trends in the business and the Company's historical operating performance on a more consistent basis. The Company believes that the use of Adjusted EBITDA and Free Cash Flow is helpful to our investors as it is used by management in assessing the health of the business, its operating performance, and its liquidity.
However, non-IFRS financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with IFRS. In addition, other companies, including companies in our industry, may calculate similarly-titled non-IFRS financial measures or ratios differently or may use other financial measures or ratios to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA or Free Cash Flow as a tool for comparison. Reconciliations are provided below to the most directly comparable financial measures stated in accordance with IFRS. Investors are encouraged to review our IFRS financial measures and not to rely on any single financial measure to evaluate our business.
Adjusted EBITDA
The Company defines Adjusted EBITDA as net income / (loss) adjusted for interest expense, depreciation and amortization, stock compensation expense, transaction expenses and, income tax (benefit) / provision, as applicable. Management believes Adjusted EBITDA is a useful supplemental measure to determine our cash burn rate related to operations so readers can understand the cash that is available to operate the business.
The following table reconciles net loss to Adjusted EBITDA for the three months ended
| Three Months Ended | ||||||
| 2026 | 2025 | |||||
| Net loss | (2,829 | ) | (1,058 | ) | ||
| Finance expense | 65 | 133 | ||||
| Income tax expense | 20 | - | ||||
| Depreciation and amortization | 360 | 205 | ||||
| Other income | - | (22 | ) | |||
| Stock compensation expense | 1,020 | - | ||||
| Go-public transaction readiness costs | 2 | 49 | ||||
| Severance | 78 | 196 | ||||
| Non-recurring expenses | 7 | 146 | ||||
| Adjusted EBITDA | $ | (1,277 | ) | $ | (351 | ) |
Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, readers should be aware that in the future the Company will incur certain expenses similar to the adjustments set out above. The Company's presentation of Adjusted EBITDA should not be construed as an inference that its future results will be unaffected by these expenses or any unusual or non-recurring items. The Company compensates for these limitations by providing specific information regarding the IFRS items excluded from Adjusted EBITDA. When evaluating the business' performance, readers should consider Adjusted EBITDA in addition to, and not as a substitute for, other financial performance measures, including our net income (loss) and other IFRS results.
Free Cash Flow
Free Cash Flow is a key performance measure that our management uses to assess our liquidity. Because Free Cash Flow facilitates internal comparisons of our historical liquidity on a more consistent basis, we use this measure for business planning purposes. Free Cash Flow is defined as net cash provided by (used in) operating activities, less purchases of property, equipment, and intangible assets and investment in internal-use software in investing activities.
The following table reconciles net cash used in operating activities to Free Cash Flow for the nine months ended
| Nine Months Ended | |||||||
| 2026 | 2025 | ||||||
| Net cash and cash equivalents used in operating activities | $ | (7,902 | ) | $ | (271 | ) | |
| Less: Purchase of property, equipment, and intangible assets in investing activities | (1,460 | ) | (1,178 | ) | |||
| Free Cash Flow | $ | (9,362 | ) | $ | (1,449 | ) | |
Some of the limitations of Free Cash Flow include (i) Free Cash Flow does not represent our residual cash flow for discretionary expenditures and our non-discretionary commitments, and (ii) Free Cash Flow includes capital expenditures, the benefits of which may be realized in periods subsequent to those in which the expenditures took place. In evaluating Free Cash Flow, you should be aware that in the future we will have cash outflows similar to the adjustments in this presentation. Our presentation of Free Cash Flow should not be construed as an inference that our future results will be unaffected by these cash outflows or any unusual or non-recurring items. When evaluating our performance, you should consider Free Cash Flow in addition to, and not as a substitute for, other financial performance measures, including our net cash used in operating activities and other IFRS results.
In addition to the non-IFRS measures described above, management monitors key business metrics to help it evaluate the business, identify trends affecting the business, formulate business plans, and make strategic decisions.
Forward-Looking Statements
This press release includes certain statements that may be deemed "forward-looking statements". All statements in this press release other than statements of historical facts including, without limitation, those that address future events, developments, or transactions that we expect, are forward-looking statements. These forward-looking statements are made as of the date of the Management Discussion & Analysis ("MD&A") of the Company dated
Forward-looking statements involve known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, but are not limited to, the factors discussed in the section entitled "Risk Factors" in the MD&A dated
For additional information, visit www.telyrx.com or contact:
Investor Relations
(647) 222-0574
investors@telyrx.com
Unaudited Consolidated Interim Statements of Financial Position
(in thousands of
As of
Unaudited
| 2026 | 2025 | |||||
| Current assets | ||||||
| Cash and cash equivalents | $ | 8,477 | $ | 2,988 | ||
| Restricted cash | 1,004 | - | ||||
| Restricted certificates of deposit | 477 | 464 | ||||
| Inventory | 1,869 | 1,352 | ||||
| Accounts receivable | 563 | 456 | ||||
| Prepaid expenses & other current assets | 1,058 | 297 | ||||
| Total current assets | 13,448 | 5,557 | ||||
| Non-current assets | ||||||
| Restricted cash | 9,196 | - | ||||
| Property and equipment, net | 977 | 714 | ||||
| Right-of-use assets | 3,129 | 2,565 | ||||
| Software, net | 1,559 | 1,040 | ||||
| Total non-current assets | 14,861 | 4,319 | ||||
| Total assets | $ | 28,309 | $ | 9,876 | ||
| Current liabilities | ||||||
| Accounts payable | $ | 3,400 | $ | 2,655 | ||
| Accrued expenses | 2,291 | 2,988 | ||||
| Contract liability | 52 | 39 | ||||
| Current portion of borrowings | 1,004 | 9,173 | ||||
| Accrued interest | 13 | 801 | ||||
| Current portion of lease liabilities | 273 | 165 | ||||
| Total current liabilities | 7,033 | 15,821 | ||||
| Non-current liabilities | ||||||
| Borrowings | 9,150 | - | ||||
| Lease liabilities | 2,996 | 2,529 | ||||
| Total non-current liabilities | 12,146 | 2,529 | ||||
| Total liabilities | 19,179 | 18,350 | ||||
| Equity | ||||||
| Shareholders' equity | 45,490 | 15,912 | ||||
| Accumulated deficit | (36,360 | ) | (24,386 | ) | ||
| Total equity | 9,130 | (8,474 | ) | |||
| Total liabilities and equity | $ | 28,309 | $ | 9,876 | ||
Unaudited Consolidated Interim Statements of Loss and Other Comprehensive Loss
(in thousands of
For the three and nine months ended
Unaudited
| Three months ended | Nine months ended | |||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||
| Revenues | $ | 23,078 | $ | 12,337 | $ | 65,142 | $ | 28,610 | ||||
| Cost of revenue | 9,303 | 5,451 | 27,644 | 13,144 | ||||||||
| Gross profit | 13,775 | 6,886 | 37,498 | 15,466 | ||||||||
| Operating expenses | ||||||||||||
| General and administrative | 16,159 | 7,628 | 47,662 | 16,919 | ||||||||
| Depreciation and amortization | 360 | 205 | 920 | 510 | ||||||||
| Total operating expenses | 16,519 | 7,833 | 48,582 | 17,429 | ||||||||
| Income (Loss) from operations | (2,744 | ) | (947 | ) | (11,084 | ) | (1,963 | ) | ||||
| Finance expense | 65 | 133 | 329 | 384 | ||||||||
| Listing expense | - | - | 2,309 | - | ||||||||
| Other income | - | (22 | ) | (1,768 | ) | (22 | ) | |||||
| Income (Loss) before tax | (2,809 | ) | (1,058 | ) | (11,954 | ) | (2,325 | ) | ||||
| Income tax expense | 20 | - | 20 | - | ||||||||
| Total net income (loss) and other comprehensive loss | $ | (2,829 | ) | $ | (1,058 | ) | $ | (11,974 | ) | $ | (2,325 | ) |
| Basic loss per share | (0.06 | ) | (0.10 | ) | (0.33 | ) | (0.22 | ) | ||||
| Diluted loss per share | (0.06 | ) | (0.10 | ) | (0.33 | ) | (0.22 | ) | ||||
Unaudited Consolidated Interim Statements of Cash Flows
(in thousands of
For the nine months ended
Unaudited
| Nine months ended | |||||||
| 2026 | 2025 | ||||||
| Cash flows from operating activities | |||||||
| Net loss | $ | (11,974 | ) | $ | (2,325 | ) | |
| Adjustments to reconcile net loss to net cash and cash equivalents provided from operating activities | |||||||
| Amortization and depreciation | 920 | 510 | |||||
| Lease interest expense | 119 | 77 | |||||
| Non-cash interest expense | 8 | 455 | |||||
| Interest earned on restricted certificates of deposit | (13 | ) | (23 | ) | |||
| Gain on lease termination | (89 | ) | - | ||||
| Stock compensation expense | 3,009 | - | |||||
| Listing expense | 2,309 | - | |||||
| Total adjustments to reconcile net loss to net cash and cash equivalents provided from operating activities | 6,263 | 1,019 | |||||
| Changes in non-cash working capital items | |||||||
| Accounts receivable | (107 | ) | (173 | ) | |||
| Inventory | (517 | ) | (650 | ) | |||
| Prepaid expenses and other current assets | (761 | ) | (179 | ) | |||
| Accounts payable | 785 | 831 | |||||
| Accrued expenses and other current liabilities | (169 | ) | 1,283 | ||||
| Total changes in non-cash working capital items | (769 | ) | 1,112 | ||||
| Interest paid | (1,422 | ) | (77 | ) | |||
| Net cash and cash equivalents used in operating activities | (7,902 | ) | (271 | ) | |||
| Cash flows from investing activities | |||||||
| Property and equipment purchases | (396 | ) | (465 | ) | |||
| Software purchases | (1,064 | ) | (713 | ) | |||
| Cash deposited as collateral for borrowings | (10,200 | ) | - | ||||
| Cash acquired in reverse takeover transaction | 827 | - | |||||
| Net cash and cash equivalents used in investing activities | (10,833 | ) | (1,178 | ) | |||
| Cash flows from financing activities | |||||||
| Proceeds from borrowings | 10,146 | - | |||||
| Repayments of borrowings | (9,213 | ) | - | ||||
| Repayment of principal portion of lease liabilities | (142 | ) | (72 | ) | |||
| Repurchase of shares from shareholder | - | (3 | ) | ||||
| Proceeds from share issuance | 23,433 | - | |||||
| Net cash and cash equivalents provided by (used in) financing activities | 24,224 | (75 | ) | ||||
| Net increase (decrease) in cash and cash equivalents | 5,489 | (1,524 | ) | ||||
| Cash and cash equivalents, beginning of period | 2,988 | 3,314 | |||||
| Cash and cash equivalents, end of period | $ | 8,477 | $ | 1,790 | |||

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/322758
SOURCE TelyRx